{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T19:41:09Z","timestamp":1762371669850,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2023\/07\/X\/NZ7\/00896"],"award-info":[{"award-number":["2023\/07\/X\/NZ7\/00896"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.drudis.2025.104331","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T21:12:41Z","timestamp":1741900361000},"page":"104331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ramipril, perindopril and trandolapril as potential chemosensitizers in ovarian cancer: Considerations for drug repurposing"],"prefix":"10.1016","volume":"30","author":[{"given":"Katarzyna","family":"Regulska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Gieremek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Michalak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Kolenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlena","family":"Janiczek-Polewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Koz\u0142owska-Mas\u0142o\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zefiryn","family":"Cybulski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata J.","family":"Stanisz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104331_b0005","doi-asserted-by":"crossref","first-page":"551","DOI":"10.5603\/RPOR.a2023.0059","article-title":"Angiotensin-converting enzyme inhibitors for ovarian cancer? \u2013 a new adjuvant option or a silent trap","volume":"28","author":"Regulska","year":"2023","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.drudis.2025.104331_b0010","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.34350","article-title":"Real-life data on treatment and outcomes in advanced ovarian cancer: an observational, multinational cohort study (RESPONSE trial)","volume":"128","author":"Christian","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2025.104331_b0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/biomedicines10010077","article-title":"Current treatments and new possible complementary therapies for epithelial ovarian cancer","volume":"10","author":"Garrido","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2025.104331_b0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.rpor.2010.02.004","article-title":"Whole abdominal radiotherapy in ovarian cancer","volume":"15","author":"Biete","year":"2010","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.drudis.2025.104331_b0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5603\/RPOR.a2021.0025","article-title":"Radiotherapy for cervical cancer: Chilean consensus of the Society of Radiation On-cology","volume":"26","author":"Carvajal","year":"2021","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.drudis.2025.104331_b0030","doi-asserted-by":"crossref","first-page":"948","DOI":"10.5603\/RPOR.a2021.0115","article-title":"Weekly vs. tri-weekly cisplatin based chemoradiation in carcinoma cervix: a prospective randomized study of toxicity and compliance","volume":"26","author":"Katke","year":"2021","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.drudis.2025.104331_b0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5603\/RPOR.a2021.0007","article-title":"Preliminary clinical outcomes of patients treated with vaginal brachytherapy alone using multi-channel vaginal brachytherapy applicator in operated early-stage endometrial cancer","volume":"26","author":"Rishi","year":"2021","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.drudis.2025.104331_b0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5603\/RPOR.a2023.0003","article-title":"Electronic brachytherapy for gynecological cancers \u2013 a systematic review","volume":"28","author":"Hitova-Topkarova","year":"2023","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.drudis.2025.104331_b0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5603\/RPOR.a2023.0025","article-title":"Morbidity of adjuvant treatment in early cervical cancer: a retrospective cohort study in a Latin American center","volume":"28","author":"Santana","year":"2023","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.drudis.2025.104331_b0050","doi-asserted-by":"crossref","first-page":"322","DOI":"10.5603\/RPOR.a2023.0031","article-title":"Ten years survival results of randomized study comparing weekly vs. triweekly cisplatin with concurrent radiation in locally advanced carcinoma cervix","volume":"28","author":"Nanda","year":"2023","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.drudis.2025.104331_b0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5603\/GP.2020.0003","article-title":"Adjuvant therapy for early endometrial cancer \u2013 who benefits the most from a radiation therapy?","volume":"91","author":"Michalak","year":"2020","journal-title":"Ginekol Pol"},{"key":"10.1016\/j.drudis.2025.104331_b0060","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231157644","article-title":"Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer","volume":"15","author":"Veneziani","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.drudis.2025.104331_b0065","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3390\/molecules25030537","article-title":"Overcoming resistance to platinum-based drugs in ovarian cancer by salinomycin and its derivatives-an in vitro study","volume":"25","author":"Michalak","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2025.104331_b0070","first-page":"6024","article-title":"DHMEQ enhances the cytotoxic effect of cisplatin and carboplatin in ovarian cancer cell lines","volume":"11","author":"Michalak","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.drudis.2025.104331_b0075","first-page":"935","article-title":"The in-volvement of small heat shock protein in chemoresistance in ovarian cancer \u2013 in vitro study","volume":"20","author":"Wyciszkiewicz","year":"2021","journal-title":"EXCLI J"},{"key":"10.1016\/j.drudis.2025.104331_b0080","first-page":"2481","article-title":"Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer","volume":"34","author":"Tsubamoto","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.drudis.2025.104331_b0085","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","article-title":"Drug repurposing: a systematic review on root causes, barriers and facilitators","volume":"22","author":"Krishnamurthy","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.drudis.2025.104331_b0090","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.drudis.2015.12.003","article-title":"COX-2 inhibitors: a novel strategy in the management of breast cancer","volume":"21","author":"Regulski","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2025.104331_b0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.drudis.2021.09.012","article-title":"Combining repurposed drugs to treat colorectal cancer","volume":"27","author":"Duarte","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2025.104331_b0100","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.drudis.2022.02.004","article-title":"Drug repurposing against SARS-CoV-2 using computational approaches","volume":"27","author":"Kumar","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2025.104331_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103684","article-title":"Repurposing drugs targeting metabolic diseases for cancer therapeutics","volume":"28","author":"Pillai","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2025.104331_b0110","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.drudis.2014.06.026","article-title":"How to design a potent, specific, and stable angiotensin-converting enzyme inhibitor","volume":"19","author":"Regulska","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2025.104331_b0115","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.2174\/1381612820666141112160013","article-title":"Chemistry and pharmacology of Angiotensin-converting enzyme inhibitors","volume":"21","author":"Regulski","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.drudis.2025.104331_b0120","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.2174\/13816128113199990508","article-title":"The renin-angiotensin system as a target of novel anticancer therapy","volume":"19","author":"Regulska","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.drudis.2025.104331_b0125","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.drudis.2019.03.010","article-title":"Can cardiovascular drugs support cancer treatment? The rationale for drug re-purposing","volume":"24","author":"Regulska","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2025.104331_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104326","article-title":"Beyond the boundaries of cardiology: Still untapped anticancer properties of the cardiovascular system-related drugs","volume":"147","author":"Regulska","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2025.104331_b0135","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2025.104331_b0140","first-page":"245","article-title":"The RNA world: from experimental laboratory to \u201cin silico\u201d approach. Part 1: User friendly RNA expression databases portals","volume":"29","author":"Kolenda","year":"2024","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.drudis.2025.104331_b0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1755-9294.2008.00035.x","article-title":"Expression of angiotensin II receptor type 1 and 2 in ovarian epithelial tumors","volume":"1","author":"Hwang","year":"2008","journal-title":"Basic Appl Pathol"},{"key":"10.1016\/j.drudis.2025.104331_b0150","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6602961","article-title":"Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival","volume":"94","author":"Ino","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2025.104331_b0155","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/1078-0432.CCR-04-1946","article-title":"Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination","volume":"11","author":"Suganuma","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104331_b0160","first-page":"1375","article-title":"The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome","volume":"21","author":"Li","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.drudis.2025.104331_b0165","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4143\/crt.2019.509","article-title":"Impact of angiotensin receptor blockers, beta blockers, calcium channel blockers and thiazide diuretics on survival of ovarian cancer patients","volume":"52","author":"Cho","year":"2020","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.drudis.2025.104331_b0170","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ygyno.2021.09.009","article-title":"Antihypertensive medication use and ovarian cancer survival","volume":"163","author":"Huang","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.drudis.2025.104331_b0175","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ygyno.2019.05.030","article-title":"Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer","volume":"154","author":"Harding","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.drudis.2025.104331_b0180","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1073\/pnas.1818357116","article-title":"Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma","volume":"116","author":"Zhao","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104331_b0185","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3390\/cancers13092087","article-title":"Antihypertensive drug use and the risk of ovarian cancer death among Finnish ovarian cancer patients-a Nationwide Cohort Study","volume":"13","author":"Santala","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2025.104331_b0190","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.3390\/ijms24043814","article-title":"Renin-angiotensin-aldosterone system inhibitors and development of gynecologic cancers: a 23 million individual population-based study","volume":"24","author":"Nguyen","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104331_b0195","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/diagnostics9030120","article-title":"Characteristics of in vitro model systems for ovarian cancer studies","volume":"9","author":"Tudrej","year":"2019","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.drudis.2025.104331_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103988","article-title":"Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes","volume":"9","author":"Beaufort","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104331_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103639","article-title":"Drug repurposing: known knowns to unknown unknowns \u2013 network analysis of the repurposome","volume":"28","author":"Cavalla","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2025.104331_b0210","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3390\/ijms24021689","article-title":"CLC-Pred 2.0: a freely available web application for in silico pre-diction of human cell line cytotoxicity and molecular mechanisms of action for druglike compounds","volume":"24","author":"Lagunin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104331_b0215","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijpharm.2013.09.002","article-title":"Is there any association between imidapril hydrochloride stability profile under dry air conditions and cancer initiation?","volume":"456","author":"Regulska","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2025.104331_b0220","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/pharmaceutics13101600","article-title":"Solid-state stability profiling of ramipril to optimize its quality efficiency and safety","volume":"13","author":"Regulska","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2025.104331_b0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263461","article-title":"Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: metaregression analysis of randomized trials","volume":"17","author":"Sipahi","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104331_b0230","first-page":"579","article-title":"Does polyvinylpyrrolidone improve the chemical stability of cilazapril in solid state?","volume":"18","author":"Regulska","year":"2019","journal-title":"Iran J Pharm Res"},{"key":"10.1016\/j.drudis.2025.104331_b0235","first-page":"737","article-title":"Kinetics of degradation of imidapril hydrochloride in finished dosage formulations","volume":"70","author":"Stanisz","year":"2013","journal-title":"Acta Pol Pharm"},{"key":"10.1016\/j.drudis.2025.104331_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2021.130987","article-title":"Degradation of ramipril by residues from the brewing industry: a new carbon-based photocatalyst compound","volume":"281","author":"Leichtweis","year":"2021","journal-title":"Chemosphere"},{"key":"10.1016\/j.drudis.2025.104331_b0245","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/ijms18010164","article-title":"Comparative solid-state stability of perindopril active substance vs. pharmaceutical formulation","volume":"18","author":"Buda","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104331_b0250","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijpharm.2012.08.048","article-title":"Impurity profiling of trandolapril under stress testing: structure elucidation of by-products and development of degradation pathway","volume":"438","author":"Dendeni","year":"2012","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2025.104331_b0255","first-page":"612","article-title":"Impact of ramipril nitroso-metabolites on cancer incidence \u2013 in silico and in vitro safety evaluation","volume":"28","author":"Regulska","year":"2023","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.drudis.2025.104331_b0260","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.rpor.2014.04.004","article-title":"The mutagenicity analysis of imidapril hydrochloride and its degradant, diketopiperazine derivative, nitrosation mixtures by in vitro Ames test with two strains of Salmonella typhimurium","volume":"19","author":"Regulska","year":"2014","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.drudis.2025.104331_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116541","article-title":"In silico and in vitro screening for carcinogenic potential of angiotensin-converting enzyme inhibitors and their degradation impurities","volume":"469","author":"Regulska","year":"2023","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.drudis.2025.104331_b0270","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3390\/app13042358","article-title":"The degradation product of ramipril is potentially carcinogenic, genotoxic and mutagenic","volume":"13","author":"Regulska","year":"2023","journal-title":"Appl Sci"},{"key":"10.1016\/j.drudis.2025.104331_b0275","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.13005\/bpj\/1498","article-title":"Evaluation of anticancer activity of olmesartan and ramipril on A549 cell line","volume":"11","author":"Gayathri","year":"2018","journal-title":"Biomed Pharmacol J"},{"key":"10.1016\/j.drudis.2025.104331_b0280","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41419-020-2675-x","article-title":"Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-\u03baB\/STAT3-regulated proteins","volume":"11","author":"Yang","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104331_b0285","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2174\/1381612820666141024151119","article-title":"Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches","volume":"21","author":"Zisaki","year":"2015","journal-title":"Curr Pharm Des"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T19:37:45Z","timestamp":1762371465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625000443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1359644625000443"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104331","relation":{},"ISSN":["1359-6446"],"issn-type":[{"type":"print","value":"1359-6446"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ramipril, perindopril and trandolapril as potential chemosensitizers in ovarian cancer: Considerations for drug repurposing","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104331"}}